Latent tuberculosis infection and biologic agents other than TNF-α inhibitors: "over-screening and over-treatment?".
作者信息
Santos Ana Paula, Mello Fernanda Carvalho de Queiroz
机构信息
. Instituto de Doenças do Tórax - IDT - Universidade Federal do Rio de Janeiro - UFRJ - Rio de Janeiro (RJ) Brasil.
. Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro - UERJ - Rio de Janeiro (RJ) Brasil.
出版信息
J Bras Pneumol. 2024 Sep 27;50(4):e20240277. doi: 10.36416/1806-3756/e20240277.
Abstract
摘要
相似文献
1
Latent tuberculosis infection and biologic agents other than TNF-α inhibitors: "over-screening and over-treatment?".潜伏性结核感染与除肿瘤坏死因子-α抑制剂之外的生物制剂：“过度筛查与过度治疗？”
J Bras Pneumol. 2024 Sep 27;50(4):e20240277. doi: 10.36416/1806-3756/e20240277.
2
Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.炎症性关节炎和潜伏性结核病的生物治疗：来自英国高患病率地区的真实世界经验。
Clin Rheumatol. 2015 Dec;34(12):2141-5. doi: 10.1007/s10067-015-3099-3. Epub 2015 Oct 24.
3
TST, QuantiFERON-TB Gold test and T-SPOT.TB test for detecting latent tuberculosis infection in patients with rheumatic disease prior to anti-TNF therapy.在抗TNF治疗前，采用结核菌素皮肤试验（TST）、结核感染T细胞检测（QuantiFERON-TB Gold试验）和T-SPOT.TB试验检测风湿病患者的潜伏性结核感染。
Tuberk Toraks. 2018 Jun;66(2):136-143. doi: 10.5578/tt.66444.
4
sQuiz editorial: Latent tuberculosis infection: Update of diagnosis before the introduction of biologic drugs.sQuiz社论：潜伏性结核感染：生物制剂引入前的诊断更新
Eur J Dermatol. 2015 Nov-Dec;25(6):629-30. doi: 10.1684/ejd.2016.2732.
5
Should all patients undergoing treatment with biologic agents be screened annually for latent tuberculosis infection with an interferon gamma release assay?是否应对所有接受生物制剂治疗的患者每年进行一次γ-干扰素释放试验，以筛查潜伏性结核感染？
J Dermatolog Treat. 2016 Aug;27(4):378-80. doi: 10.3109/09546634.2015.1115815. Epub 2015 Dec 10.
6
Can ELISpot replace the tuberculin skin test for latent tuberculosis?酶联免疫斑点技术（ELISpot）能否替代结核菌素皮肤试验用于潜伏性结核的检测？
Br J Nurs. 2009;18(20):1248-54. doi: 10.12968/bjon.2009.18.20.45120.
7
Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient.生物治疗候选者中结核感染的预防与治疗：一份适用于皮肤科患者的多学科共识声明
Actas Dermosifiliogr (Engl Ed). 2018 Sep;109(7):584-601. doi: 10.1016/j.ad.2018.03.013. Epub 2018 Jun 2.
8
9
Comparison of a commercial interferon-gamma release assay and tuberculin skin test for the detection of latent tuberculosis infection in Hong Kong arthritis patients who are candidates for biologic agents.在香港有资格使用生物制剂的关节炎患者中，比较一种商用γ-干扰素释放试验和结核菌素皮肤试验用于检测潜伏性结核感染的情况。
Hong Kong Med J. 2017 Jun;23(3):246-50. doi: 10.12809/hkmj164880. Epub 2017 Jan 27.
10
Tuberculosis screening before biologic therapy. Comment about the article entitled "role for interferon-gamma release assays in latent tuberculosis screening before TNF-α antagonist therapy" by Liote H et al.生物治疗前的结核病筛查。评Liote H等人发表的题为“γ干扰素释放试验在TNF-α拮抗剂治疗前潜伏性结核病筛查中的作用”的文章
Joint Bone Spine. 2011 Dec;78(6):655-6; author reply 656-7. doi: 10.1016/j.jbspin.2011.07.002. Epub 2011 Sep 15.
引用本文的文献
1
Infection Risk and Vaccination in the Management of Psoriasis: Considerations for Biologic Therapy.银屑病管理中的感染风险与疫苗接种：生物治疗的考量
Psoriasis (Auckl). 2025 Apr 11;15:127-144. doi: 10.2147/PTT.S510141. eCollection 2025.
本文引用的文献
1
Expert views on screening for tuberculosis infection in patients commencing treatment with a biologic agent.关于开始使用生物制剂治疗的患者进行结核感染筛查的专家观点。
J Bras Pneumol. 2024 Sep 27;50(4):e20240082. doi: 10.36416/1806-3756/e20240082. eCollection 2024.
2
Latent Tuberculosis: Challenges in Diagnosis and Treatment, Perspectives, and the Crucial Role of Biomarkers.潜伏性结核：诊断与治疗的挑战、观点，以及生物标志物的关键作用。
Curr Microbiol. 2023 Oct 27;80(12):392. doi: 10.1007/s00284-023-03491-x.
3
2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases.2022 年 EULAR 成人自身免疫性炎症性风湿病患者慢性和机会性感染筛查和预防的建议。
Ann Rheum Dis. 2023 Jun;82(6):742-753. doi: 10.1136/ard-2022-223335. Epub 2022 Nov 3.
4
Screening for Latent Tuberculosis and Biological Therapy.潜伏性结核病筛查与生物治疗
Arch Bronconeumol (Engl Ed). 2020 Mar;56(3):139-140. doi: 10.1016/j.arbres.2019.04.008. Epub 2019 May 22.
5
Biologic Agents and Tuberculosis.生物制剂与结核病。
Microbiol Spectr. 2016 Dec;4(6). doi: 10.1128/microbiolspec.TNMI7-0026-2016.
6
Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts.免疫介导性炎症疾病中的生物疗法：基础科学与临床概念
Curr Drug Saf. 2016;11(1):35-43. doi: 10.2174/1574886310666151014115127.
7
Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.抗TNF与免疫抑制剂联合使用时结核病再激活风险更高：随机对照试验的系统评价
Ann Med. 2014 Nov;46(7):547-54. doi: 10.3109/07853890.2014.941919. Epub 2014 Aug 8.
8
Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?肿瘤坏死因子及其在肉芽肿性感染中的阻断作用：英夫利昔单抗和依那西普的不同作用模式？
Clin Infect Dis. 2005 Aug 1;41 Suppl 3:S199-203. doi: 10.1086/429998.
9
Increased risk of tuberculosis in patients with rheumatoid arthritis.类风湿关节炎患者患结核病的风险增加。
J Rheumatol. 2003 Jul;30(7):1436-9.
10
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.与英夫利昔单抗（一种肿瘤坏死因子α中和剂）相关的结核病。
N Engl J Med. 2001 Oct 11;345(15):1098-104. doi: 10.1056/NEJMoa011110.
Zotero 插件